Home › NDC Lookup › Ingredients › Enoxaparin Sodium › 11797-0762-06
Enoxaparin Sodium 120 mg/.8mL Injection, Solution, 10 syringes — NDC 11797-0762-06 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Enoxaparin Sodium 120 mg/.8mL Injection, Solution, 10 syringes — NDC 11797-762-06 (Billing 11797-0762-06)

by Italfarmaco SpA · 10 SYRINGE in 1 CARTON / .8 mL in 1 SYRINGE

This is a package of 10 syringes of Enoxaparin Sodium 120 mg/.8mL Injection, Solution from Italfarmaco SpA, marketed since Apr 2021 and currently FDA-listed. It is this product's only package size.

NDC 11797-0762-06
🏷️ FDA NDC (as labeled) 11797-762-06 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Enoxaparin Sodium (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 5, 2025 — Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, contained Enoxaparin Sodium Injection, 30 mg/0.3 mL (Cardinal Health Inc.) · FDA recall D-0597-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 11797-762-06
Product NDC 11797-762
11-digit billing NDC 11797076206
RxCUI 854228, 854235, 854238, 854241, 854245, 854248, 854252
UNII 8NZ41MIK1O
Application # ANDA076726
SPL Set ID b4d9e4d4-4fdb-48d6-a169-7bc5eebc51e9
Established class (EPC) Heparin; Low Molecular Weight Heparin
Chemical class Low-Molecular-Weight
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-04-01
Route INTRAVENOUS, SUBCUTANEOUS
Dosage form INJECTION, SOLUTION
Substance ENOXAPARIN SODIUM
TE code (Orange Book) AP · RLD · RS
Quick answers
  • RxCUI (RxNorm): 854228
Why two NDCs? The FDA registers this code as 11797-762-06 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 11797-0762-06. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Low Molecular Weight Heparin class.

Pharmacologic class Low Molecular Weight Heparin
Drug family (ATC) Heparin group
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Enoxaparin is used to prevent and treat deep vein thrombosis (DVT; blood clots that form in the veins, typically in the legs). It is also used to prevent complications from angina (chest pain) and heart attacks. Enoxaparin is in a class of medications called low molecular weight heparins. It works by stopping the formation of substances that cause clots.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is a blood thinner that helps prevent and treat deep vein thrombosis, a clot in a deep vein. It is also used in unstable angina and certain heart attacks. Your prescriber choose...
  • It is an injection, usually under the skin, and some uses involve an injection into a vein. How often depends on why you need it. Follow your prescriber’s directions and the produc...
  • Bruising, injection site pain, nausea and diarrhea are common. Some people have bleeding or a lower blood count. Call your doctor if bleeding seems unusual or won’t stop.
  • Yes. If you have an epidural or spinal procedure, bleeding near the spine can rarely cause permanent paralysis. Report new numbness, leg weakness or bladder or bowel changes right...
📖 Read our full Enoxaparin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
1
Nutrient depletion considerations

Enoxaparin may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Enoxaparin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $10.33 $82.66 / 8 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
11797-0762-06 You're viewing this Main listing 10 SYRINGE in 1 CARTON / .8 mL in 1 SYRINGE 2021-04-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Enoxaparin Sodium 150 mg/mL 00548-5606-00 Amphastar 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 00781-3298-68 Sandoz 10 syringes $10.417 AP Availability likely —
Enoxaparin sodium 120 mg/.8mL 00955-1012-10 Sanofi-Aventis 10 cellos $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 16714-0056-10 NorthStar 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 25021-0411-70 Sagent 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 120 mg/.8mL 63323-0655-99 Fresenius 1 syringe $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 68001-0638-42 BluePoint 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 120 mg/.8mL 70710-1762-06 Zydus 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 71288-0437-94 Meitheal 10 syringes $10.417 AP Availability likely —
enoxaparin sodium 120 mg/.8mL 71839-0115-10 BE 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 120 mg/.8mL 81952-0132-28 Hepalink 10 syringes $10.417 AP Availability likely —
Enoxaparin Sodium 150 mg/mL 68001-0462-42 BluePoint 10 syringes $11.810 AP Availability likely —
Enoxaparin Sodium 120 mg/.8mL 72603-0215-10 NorthStar 10 syringes $17.382 AP FDA listed —
Lovenox 120 mg/.8mL 00075-2912-01 Sanofi-Aventis 10 cellos — AP FDA listed —
Lovenox 120 mg/.8mL 00075-8022-10 Sanofi-Aventis 10 cellos — AP FDA listed —
Enoxaparin Sodium 120 mg/.8mLthis 11797-0762-06 Italfarmaco 10 syringes — AP FDA listed —
enoxaparin sodium 120 mg/.8mL 28955-0106-10 Hebei 10 syringes — AP FDA listed —
Enoxaparin Sodium 120 mg/.8mL 63323-0609-98 Fresenius 10 cellos — AP FDA listed —
Enoxaparin Sodium 120 mg/.8mL 68083-0639-10 Gland 10 syringes — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Apr 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerItalfarmaco SpA
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA076726 (ANDA)
Labeler code11797
First marketedApr 2021
Product typeHuman Prescription Drug
Portfolio11 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel
📄 Package Label / Principal Display Panel 172 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 11797-757-06 Enoxaparin Sodium Injection USP 30 mg/0.3 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 0.3 mL Syringes NDC 11797-758-06 Enoxaparin Sodium Injection USP 40 mg/0.4 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 0.4 mL Syringes NDC 11797-759-06 Enoxaparin Sodium Injection USP 60 mg/0.6 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 0.6 mL Syringes NDC 11797-760-06 Enoxaparin Sodium Injection USP 80 mg/0.8 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 0.8 mL Syringes NDC 11797-761-06 Enoxaparin Sodium Injection USP 100 mg/1 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 1 mL Syringes NDC 11797-762-06 Enoxaparin Sodium Injection USP 120 mg/0.8 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 0.8 mL Syringes NDC 11797-763-06 Enoxaparin Sodium Injection USP 150 mg/1 mL SINGLE-DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE FOR SUBCUTANEOUS INJECTION Ten 1 mL Syringes 30 mg 40 mg 60 mg 80 mg 100 mg 120 mg 150 mg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Enoxaparin Sodium — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Enoxaparin Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$20.1M
Claims incl. refills
131.2K
Beneficiaries
84K
Spend / beneficiary
$239.28
Spend / claim
$153.24
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Italfarmaco SpA. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Italfarmaco SpA is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 11797-0761-06 · Italfarmaco 11797-0763-06 · Italfarmaco →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.